OTLK
Outlook Therapeutics, Inc.
Biotechnology
Market Cap$14M
5Y Perf.-98.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
OTLK vs REPL vs ALNY vs IQV
Revenue, margins, valuation, and 5-year total return — side by side.
REPL
Replimune Group, Inc.
Biotechnology
Market Cap$324M
5Y Perf.-78.3%
ALNY
Alnylam Pharmaceuticals, Inc.
Biotechnology
Market Cap$39.37B
5Y Perf.+118.1%
IQV
IQVIA Holdings Inc.
Medical - Diagnostics & Research
Market Cap$30.33B
5Y Perf.+19.5%
OTLK vs REPL vs ALNY vs IQV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OTLK | REPL | ALNY | IQV |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $14M | $324M | $39.37B | $30.33B |
| Revenue (TTM) | $206K | $0.00 | $4.29B | $16.63B |
| Net Income (TTM) | $-103M | $-315M | $577M | $1.39B |
| Gross Margin | -5.9% | — | 80.9% | 26.1% |
| Operating Margin | -286.8% | — | 17.5% | 13.9% |
| Forward P/E | — | — | 39.9x | 14.0x |
| Total Debt | $247.70B | $76M | $1.28B | $16.17B |
| Cash & Equiv. | $8.08T | $111M | $1.66B | $1.98B |
OTLK vs REPL vs ALNY vs IQV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OTLK
REPL
ALNY
IQV
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Outlook Therapeutic… (OTLK) | 100 | 1.1 | -98.9% |
| Replimune Group, In… (REPL) | 100 | 21.7 | -78.3% |
| Alnylam Pharmaceuti… (ALNY) | 100 | 218.1 | +118.1% |
| IQVIA Holdings Inc. (IQV) | 100 | 119.5 | +19.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OTLK vs REPL vs ALNY vs IQV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALNY leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. IQVIA Holdings Inc. is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
OTLK
Outlook Therapeutics, Inc.
The Income Pick
OTLK is the clearest fit if your priority is income & stability.
- Dividend streak 2 yrs, beta 1.47
Best for: income & stability
REPL
Replimune Group, Inc.
The Defensive Pick
REPL is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.80, Low D/E 18.3%, current ratio 7.95x
Best for: sleep-well-at-night
ALNY
Alnylam Pharmaceuticals, Inc.
The Growth Play
ALNY carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 65.2%, EPS growth 206.9%, 3Y rev CAGR 53.0%
- 410.4% 10Y total return vs IQV's 166.6%
- Beta 0.74, current ratio 2.76x
- 65.2% revenue growth vs REPL's -39.7%
Best for: growth exposure and long-term compounding
IQV
IQVIA Holdings Inc.
The Value Play
IQV is the #2 pick in this set and the best alternative if value and momentum is your priority.
- Lower P/E (14.0x vs 39.9x)
- +16.6% vs OTLK's -84.6%
Best for: value and momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ALNY | 65.2% revenue growth vs REPL's -39.7% |
| Value | IQV | Lower P/E (14.0x vs 39.9x) |
| Quality / Margins | ALNY | 13.5% margin vs OTLK's -500.5% |
| Stability / Safety | ALNY | Beta 0.74 vs OTLK's 1.47 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | IQV | +16.6% vs OTLK's -84.6% |
| Efficiency (ROA) | ALNY | 11.8% ROA vs REPL's -94.4%, ROIC 33.4% vs -51.9% |
OTLK vs REPL vs ALNY vs IQV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2025
OTLK vs REPL vs ALNY vs IQV — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLALNYLAGGINGREPL
Who Leads Where
ALNY leads in 3 of 6 categories
IQV leads 1 • OTLK leads 0 • REPL leads 0 • 1 tied
Explore the data ↓REPLReplimune Group, Inc.
0leads
OTLKOutlook Therapeutics,…
0leads
IQVIQVIA Holdings Inc.
1leads
ALNYAlnylam Pharmaceutica…
3leads
6 Total Categories
CATEGORYLEADERvs IQVvs OTLKMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALNY5/6
Valuation MetricsMultiples, price ratios, and targets
IQV4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALNY5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ALNY4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ALNY leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IQV and REPL operate at a comparable scale, with $16.6B and $0 in trailing revenue. ALNY is the more profitable business, keeping 13.5% of every revenue dollar as net income compared to OTLK's -500.5%. On growth, ALNY holds the edge at +96.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … | ALNYAlnylam Pharmaceu… | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $205,535 | $0 | $4.3B | $16.6B |
| EBITDAEarnings before interest/tax | -$59M | -$323M | $677M | $3.5B |
| Net IncomeAfter-tax profit | -$103M | -$315M | $577M | $1.4B |
| Free Cash FlowCash after capex | -$14.94T | -$283M | $641M | $2.7B |
| Gross MarginGross profit ÷ Revenue | -5.9% | — | +80.9% | +26.1% |
| Operating MarginEBIT ÷ Revenue | -286.8% | — | +17.5% | +13.9% |
| Net MarginNet income ÷ Revenue | -500.5% | — | +13.5% | +8.3% |
| FCF MarginFCF ÷ Revenue | -999999.0% | — | +15.0% | +16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +96.4% | +8.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -152.8% | +2.5% | +4.4% | +15.0% |
ALNY leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
IQV leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 22.8x trailing earnings, IQV trades at a 82% valuation discount to ALNY's 126.6x P/E. On an enterprise value basis, IQV's 13.0x EV/EBITDA is more attractive than ALNY's 70.0x.
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … | ALNYAlnylam Pharmaceu… | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| Market CapShares × price | $14M | $324M | $39.4B | $30.3B |
| Enterprise ValueMkt cap + debt − cash | -$7.84T | $289M | $39.0B | $44.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.12x | -1.33x | 126.63x | 22.79x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 39.92x | 13.96x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.56x |
| EV / EBITDAEnterprise value multiple | — | — | 69.97x | 12.98x |
| Price / SalesMarket cap ÷ Revenue | 10.11x | — | 10.60x | 1.86x |
| Price / BookPrice ÷ Book value/share | — | 0.79x | 50.35x | 4.68x |
| Price / FCFMarket cap ÷ FCF | — | — | 84.59x | 14.79x |
IQV leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
ALNY leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ALNY delivers a 98.3% return on equity — every $100 of shareholder capital generates $98 in annual profit, vs $-150 for REPL. REPL carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), ALNY scores 6/9 vs REPL's 2/9, reflecting solid financial health.
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … | ALNYAlnylam Pharmaceu… | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -149.5% | +98.3% | +22.1% |
| ROA (TTM)Return on assets | -0.0% | -94.4% | +11.8% | +4.7% |
| ROICReturn on invested capital | — | -51.9% | +33.4% | +8.7% |
| ROCEReturn on capital employed | — | -55.9% | +15.3% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 6 | 4 |
| Debt / EquityFinancial leverage | — | 0.18x | 1.62x | 2.44x |
| Net DebtTotal debt minus cash | -$7.84T | -$35M | -$379M | $14.2B |
| Cash & Equiv.Liquid assets | $8.08T | $111M | $1.7B | $2.0B |
| Total DebtShort + long-term debt | $247.7B | $76M | $1.3B | $16.2B |
| Interest CoverageEBIT ÷ Interest expense | -182.41x | -48.62x | 2.02x | 3.10x |
ALNY leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ALNY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALNY five years ago would be worth $22,938 today (with dividends reinvested), compared to $56 for OTLK. Over the past 12 months, IQV leads with a +16.6% total return vs OTLK's -84.6%. The 3-year compound annual growth rate (CAGR) favors ALNY at 12.0% vs OTLK's -78.7% — a key indicator of consistent wealth creation.
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … | ALNYAlnylam Pharmaceu… | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -66.5% | -54.3% | -26.3% | -20.7% |
| 1-Year ReturnPast 12 months | -84.6% | -47.6% | +14.2% | +16.6% |
| 3-Year ReturnCumulative with dividends | -99.0% | -77.5% | +40.5% | -5.9% |
| 5-Year ReturnCumulative with dividends | -99.4% | -88.0% | +129.4% | -22.8% |
| 10-Year ReturnCumulative with dividends | -100.0% | -73.2% | +410.4% | +166.6% |
| CAGR (3Y)Annualised 3-year return | -78.7% | -39.1% | +12.0% | -2.0% |
ALNY leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ALNY and IQV each lead in 1 of 2 comparable metrics.
Risk & Volatility
ALNY is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than OTLK's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IQV currently trades 72.3% from its 52-week high vs OTLK's 6.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … | ALNYAlnylam Pharmaceu… | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.47x | 0.80x | 0.74x | 1.32x |
| 52-Week HighHighest price in past year | $3.39 | $13.24 | $495.55 | $247.05 |
| 52-Week LowLowest price in past year | $0.16 | $1.50 | $245.96 | $134.65 |
| % of 52W HighCurrent price vs 52-week peak | +6.5% | +30.7% | +59.5% | +72.3% |
| RSI (14)Momentum oscillator 0–100 | 38.3 | 45.5 | 39.9 | 60.3 |
| Avg Volume (50D)Average daily shares traded | 4.0M | 5.9M | 1.1M | 1.5M |
Evenly matched — ALNY and IQV each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: REPL as "Buy", ALNY as "Buy", IQV as "Buy". Consensus price targets imply 244.0% upside for REPL (target: $14) vs 25.2% for IQV (target: $224).
| Metric | OTLKOutlook Therapeut… | REPLReplimune Group, … | ALNYAlnylam Pharmaceu… | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $14.00 | $445.67 | $223.75 |
| # AnalystsCovering analysts | — | 15 | 52 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 2 | — | — | 2 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +4.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
ALNY leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IQV leads in 1 (Valuation Metrics). 1 tied.
Best OverallAlnylam Pharmaceuticals, In… (ALNY)Leads 3 of 6 categories
Loading custom metrics...
OTLK vs REPL vs ALNY vs IQV: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is OTLK or REPL or ALNY or IQV a better buy right now?
For growth investors, Alnylam Pharmaceuticals, Inc.
(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Replimune Group, Inc. (REPL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OTLK or REPL or ALNY or IQV?
On trailing P/E, IQVIA Holdings Inc.
(IQV) is the cheapest at 22. 8x versus Alnylam Pharmaceuticals, Inc. at 126. 6x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 0x.
03Which is the better long-term investment — OTLK or REPL or ALNY or IQV?
Over the past 5 years, Alnylam Pharmaceuticals, Inc.
(ALNY) delivered a total return of +129. 4%, compared to -99. 4% for Outlook Therapeutics, Inc. (OTLK). Over 10 years, the gap is even starker: ALNY returned +410. 4% versus OTLK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OTLK or REPL or ALNY or IQV?
By beta (market sensitivity over 5 years), Alnylam Pharmaceuticals, Inc.
(ALNY) is the lower-risk stock at 0. 74β versus Outlook Therapeutics, Inc. 's 1. 47β — meaning OTLK is approximately 98% more volatile than ALNY relative to the S&P 500. On balance sheet safety, Replimune Group, Inc. (REPL) carries a lower debt/equity ratio of 18% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — OTLK or REPL or ALNY or IQV?
By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.
(ALNY) is pulling ahead at 65. 2% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to 4. 7% for IQVIA Holdings Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OTLK or REPL or ALNY or IQV?
Alnylam Pharmaceuticals, Inc.
(ALNY) is the more profitable company, earning 8. 4% net margin versus -44. 2% for Outlook Therapeutics, Inc. — meaning it keeps 8. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -47. 4% for OTLK. At the gross margin level — before operating expenses — ALNY leads at 81. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OTLK or REPL or ALNY or IQV more undervalued right now?
On forward earnings alone, IQVIA Holdings Inc.
(IQV) trades at 14. 0x forward P/E versus 39. 9x for Alnylam Pharmaceuticals, Inc. — 26. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REPL: 244. 0% to $14. 00.
08Which pays a better dividend — OTLK or REPL or ALNY or IQV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is OTLK or REPL or ALNY or IQV better for a retirement portfolio?
For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.
(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74), +410. 4% 10Y return). Both have compounded well over 10 years (ALNY: +410. 4%, OTLK: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OTLK and REPL and ALNY and IQV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OTLK is a small-cap quality compounder stock; REPL is a small-cap quality compounder stock; ALNY is a mid-cap high-growth stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.